Infectious risk of plasma donations: Relationship to safety of intravenous immune globulins

被引:15
作者
Dodd, RY
机构
[1] American Red Cross, Holland Laboratory, Rockville, MD
[2] American Red Cross, Holland Laboratory, Rockville, MD 20855
关键词
immunoglobulin; intravenous immune globulin; infection; safety; human immunodeficiency virus; hepatitis C virus;
D O I
10.1111/cei.1996.104.s1.31
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although intravenous immune globulin (IVIG) preparations may be derived from tens of thousands of donations, the residual risk of viral contamination of recovered plasma appears remarkably low, at least for human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Consequently, most pools are unlikely to contain these viruses although the situation is not as well understood for US-derived source plasma. In addition, routine preparation methods are likely to eliminate infectivity from the relatively fragile HIV. Current plasma screening measures are generally designed to maintain reasonable titres of anti-HBs in pools, perhaps contributing to the absence of HBV infection. The situation with respect to hepatitis C virus (HCV) is not well understood and it appears that sensitive screening for anti-HCV may have had an impact on the safety of at least one IVIG preparation. The implementation of effective viral inactivation procedures is expected to eliminate any further risk of HCV infection from IVIG preparations.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 25 条
[1]   FREQUENT PATIENT-TO-PATIENT TRANSMISSION OF HEPATITIS-C VIRUS IN A HEMATOLOGY WARD [J].
ALLANDER, T ;
GRUBER, A ;
NAGHAVI, M ;
BEYENE, A ;
SODERSTROM, T ;
BJORKHOLM, M ;
GRILLNER, L ;
PERSSON, MAA .
LANCET, 1995, 345 (8950) :603-607
[2]  
Alter Miriam J., 1995, P23
[3]   THE EFFECT ON THE SAFETY OF INTRAVENOUS IMMUNOGLOBULIN OF TESTING PLASMA FOR ANTIBODY TO HEPATITIS-C [J].
BISWAS, RM ;
NEDJAR, S ;
WILSON, LT ;
MITCHELL, FD ;
SNOY, PJ ;
FINLAYSON, JS ;
TANKERSLEY, DL .
TRANSFUSION, 1994, 34 (02) :100-104
[4]   CHEMICAL DISINFECTION OF CREUTZFELDT-JAKOB DISEASE VIRUS [J].
BROWN, P ;
GIBBS, CJ ;
AMYX, HL ;
KINGSBURY, DT ;
ROHWER, RG ;
SULIMA, MP ;
GAJDUSEK, DC .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (21) :1279-1282
[5]   EVALUATION OF SCREENED BLOOD DONATIONS FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION BY CULTURE AND DNA AMPLIFICATION OF POOLED CELLS [J].
BUSCH, MP ;
EBLE, BE ;
KHAYAMBASHI, H ;
HEILBRON, D ;
MURPHY, EL ;
KWOK, S ;
SNINSKY, J ;
PERKINS, HA ;
VYAS, GN .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (01) :1-5
[6]   TIME-COURSE OF DETECTION OF VIRAL AND SEROLOGIC MARKERS PRECEDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SEROCONVERSION - IMPLICATIONS FOR SCREENING OF BLOOD AND TISSUE DONORS [J].
BUSCH, MP ;
LEE, LLL ;
SATTEN, GA ;
HENRARD, DR ;
FARZADEGAN, H ;
NELSON, KE ;
READ, S ;
DODD, RY ;
PETERSEN, LR .
TRANSFUSION, 1995, 35 (02) :91-97
[7]   THE RISK OF TRANSFUSION-TRANSMITTED INFECTION [J].
DODD, RY .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (06) :419-421
[8]   THE DECLINING RISK OF POSTTRANSFUSION HEPATITIS-C VIRUS-INFECTION [J].
DONAHUE, JG ;
MUNOZ, A ;
NESS, PM ;
BROWN, DE ;
YAWN, DH ;
MCALLISTER, HA ;
REITZ, BA ;
NELSON, KE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (06) :369-373
[9]   CREUTZFELDT-JAKOB DISEASE AND BLOOD-TRANSFUSION [J].
ESMONDE, TFG ;
WILL, RG ;
SLATTERY, JM ;
KNIGHT, R ;
HARRIESJONES, R ;
DESILVA, R ;
MATTHEWS, WB .
LANCET, 1993, 341 (8839) :205-207
[10]   VIRAL SAFETY OF CLOTTING FACTOR CONCENTRATES [J].
FRICKE, WA ;
LAMB, MA .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 (01) :54-61